Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3140803 | 0.97 | TP53 (0.44) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL7793452 | 0.94 | TP53 (0.42) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL29019093 | 0.91 | TP53 (0.40) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL27714775 | 0.90 | TP53 (0.44) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL29019090 | 0.88 | TP53 (0.38) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL28640592 | 0.87 | DPP4 (0.35) | TP53DPP8DPP4 | |
| Trifluoroacetic Acid SCHEMBL72727 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL7647467 | 0.86 | TP53 (0.36) | TP53DPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL28128351 | 0.85 | FAAH (0.50) | — | |
| Trifluoroacetic Acid SCHEMBL1833665 | 0.85 | TP53 (0.40) | TP53ALDH1A1TSHRDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470870-B2 | Solid forms of an anti-HIV phosphoindole compound | IDENIX PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110039803-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX PHARMACEUTICALS, INC. | 2011-02-17 | — | — | US | disclosed |
| EP-2276771-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120914-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | THOMPSON WAYNE (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039803-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | PSPH, PPP5C, PPIP5K2 | TP53 196/4885ALDH1A1 4256/4885LMNA 3231/4885 |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | GRIN2B, GRIN3A, GRIN2A | TP53 3924/4885ALDH1A1 636/4885LMNA 2149/4885 |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | GRIN2B, GRIN1, GRIN2A | TP53 3847/4885ALDH1A1 638/4885LMNA 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.